Department of Orthopaedic Surgery, Leiden University Medical Center, Leiden, the Netherlands.
Department of Cell and Chemical biology, Leiden University Medical Center, Leiden, the Netherlands.
Histopathology. 2019 Jan;74(2):332-340. doi: 10.1111/his.13744. Epub 2018 Nov 11.
Localised- and diffuse-type tenosynovial giant cell tumours (TGCT) are regarded as different clinical and radiological TGCT types. However, genetically and histopathologically they seem indistinguishable. We aimed to correlate CSF1 expression and CSF1 rearrangement with the biological behaviour of different TGCT-types with clinical outcome (recurrence).
Along a continuum of extremes, therapy-naive knee TGCT patients with >3-year follow-up, mean age 43 (range = 6-71) years and 56% females were selected. Nine localised (two recurrences), 16 diffuse-type (nine recurrences) and four synovitis as control were included. Rearrangement of the CSF1 locus was evaluated with split-apart fluorescence in-situ hybridisation (FISH) probes. Regions were selected to score after identifying CSF1-expressing regions, using mRNA ISH with the help of digital correlative microscopy. CSF1 rearrangement was considered positive in samples containing >2 split signals/100 nuclei. Irrespective of TGCT-subtype, all cases showed CSF1 expression and in 76% CSF1 rearrangement was detected. Quantification of CSF1-expressing cells was not informative, due to the extensive intratumour heterogeneity. Of the four synovitis cases, two also showed CSF1 expression without CSF1 rearrangement. No correlation between CSF1 expression or rearrangement with clinical subtype and local recurrence was detected. Both localised and diffuse TGCT cases showed a scattered distribution in the tissue of CSF1-expressing cells.
In diagnosing TGCT, CSF1 mRNA-ISH, in combination with CSF1 split-apart FISH using digital correlative microscopy, is an auxiliary diagnostic tool to identify rarely occurring neoplastic cells. This combined approach allowed us to detect CSF1 rearrangement in 76% of the TGCT cases. Neither CSF1 expression nor presence of CSF1 rearrangement could be associated with the difference in biological behaviour of TGCT.
局限性和弥漫性腱鞘巨细胞瘤(TGCT)被认为是两种不同的临床和影像学 TGCT 类型。然而,从遗传学和组织病理学上看,它们似乎没有区别。我们旨在将 CSF1 表达和 CSF1 重排与不同 TGCT 类型的生物学行为相关联,并与临床结果(复发)相关联。
沿着极端的连续体,选择了未经治疗的膝部 TGCT 患者,这些患者有 >3 年的随访,平均年龄为 43 岁(范围为 6-71 岁),女性占 56%。纳入了 9 例局限性(2 例复发)、16 例弥漫性(9 例复发)和 4 例滑膜炎作为对照。使用分离荧光原位杂交(FISH)探针评估 CSF1 基因座的重排。在用数字相关显微镜辅助的 mRNAISH 识别 CSF1 表达区域后,选择区域进行评分。CSF1 重排被认为是在含有 >2 个分离信号/100 个核的样本中阳性的。无论 TGCT 亚型如何,所有病例均显示 CSF1 表达,并且在 76%的病例中检测到 CSF1 重排。由于肿瘤内异质性广泛,CSF1 表达细胞的定量没有信息。在四个滑膜炎病例中,有两个也显示出 CSF1 表达而没有 CSF1 重排。未检测到 CSF1 表达或重排与临床亚型和局部复发之间的相关性。局限性和弥漫性 TGCT 病例的 CSF1 表达细胞在组织中呈散在分布。
在诊断 TGCT 时,CSF1 mRNA-ISH 结合数字相关显微镜使用 CSF1 分离 FISH 是一种辅助诊断工具,可用于识别罕见的肿瘤细胞。这种联合方法使我们能够在 76%的 TGCT 病例中检测到 CSF1 重排。CSF1 表达或 CSF1 重排均不能与 TGCT 生物学行为的差异相关联。